TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The N-ABLE Study)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Among other criteria, patients must meet all of the following conditions to be eligible to be in the study:~1. 18 years of age or older.~2. Newly diagnosed muscle-invasive transitional cell (urothelial) bladder cancer where neoadjuvant chemotherapy and radical cystectomy with curative intent are indicated (i.e., American Joint Committee on Cancer (AJCC) stage T2-4a, Nany, M0). Patients must be entered into the study within eight weeks of their most recent diagnostic procedure, which is usually a diagnostic biopsy or transurethral resection of bladder tumor (TURBT) procedure.~3. Histopathologically confirmed, transitional cell (urothelial) carcinoma. Urothelial tumors with mixed histology (but with \<50% variant) are eligible.~4. Tumor tissue (obtained during a prior procedure) confirmed to express hCG-β by a central laboratory.~5. Candidate for therapy with neoadjuvant chemotherapy.~Exclusion Criteria:~Among other criteria, patients who meet any of the following conditions are NOT eligible to be in the study:~1. Previous systemic chemotherapy or radiation for bladder cancer. Note: Prior immunotherapy or intravesical (administered within the bladder) chemotherapy for superficial disease is acceptable.~2. History of anaphylactic reaction following exposure to humanized or human therapeutic monoclonal antibodies, hypersensitivity to GM-CSF or yeast derived products, clinically meaningful allergic reactions to imiquimod, resiquimod, or any known hypersensitivity or prior reaction to any of the formulation excipients in the study drugs.~3. Concurrent chronic treatment with immunosuppressive or immunomodulatory agents, including any systemic steroid (exception: inhaled or topically applied steroids, and acute and chronic standard dose NSAIDs, are permitted).~4. Known infection with HIV, HBV or HCV.~5. Any underlying medical condition that, in the Investigator's opinion, will make the administration of study vaccine hazardous to the patient, would obscure the interpretation of adverse events, or would contraindicate receipt of neoadjuvant chemotherapy or surgical resection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CDX-1307 Vaccine Regimen (Type: EXPERIMENTAL): Chemotherapy with CDX-1307 vaccine regimen (neoadjuvant phase), followed by bladder removal surgery (cystectomy). CDX-1307 vaccine regimen will continue to be given for up-to 1 year post-surgery (adjuvant/long-term follow-up phase).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Extension Neoadjuvant Taxotere: Study of the Effects of Taxotere in Patients With Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. All patients must be female~2. Locally advanced breast cancers or primary breast cancers with concomitant gross metastatic disease are eligible; locally advanced cancers must be of clinical and/or radiologic size \> 4 cm and/or are deemed surgically inoperable.~3. Negative serum pregnancy test (beta-human chorionic gonadotropin \[b-HCG\]) within 7 days of starting study, if of childbearing potential~4. Kidney and liver function tests - all within 1.5 times of the institution's upper limit of normal~5. Performance status (World Health Organization \[WHO\] scale) \< 2 and life expectancy \> 6 months~6. Age \> 18 years old~7. No brain and/or leptomeningeal disease~8. No previous or current malignancies at other sites within the last 5 years, with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin.~Exclusion Criteria:~1. Pregnancy or unwillingness to use a reliable contraceptive method in women of child-bearing potential.~2. Severe underlying chronic illness or disease~3. Patients on other investigational drugs while on study will be excluded.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Prospective Observational Registry of Primary Headache Patients Treated With Ausanil

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Men and women aged 18 to 80 years~* Primary Headache disorder as per International Classification of Headache Disorders-11~* Ausanil naive~* Signed dated informed consent~* Females of childbearing potential must be using adequate contraception during study period.~* Willing and able to comply with registry requirements to document headache response~Exclusion Criteria:~* Known allergy to Ausanil or any of its ingredients~* Active bronchial asthma that in the opinion of the investigator would interfere with use of Ausanil~* Nasal obstruction due to any cause or extensive nasal surgery resulting in scarring or other such impact on nasal mucosa that might lead to heightened sensitivity to Ausanil in the opinion of the investigator.~* Pregnant or breast feeding females~* History of addictive behavior~* Any severe or chronic unstable medical or psychiatric condition~* Active nasal infection or inflammation~* Unable or unwilling to provide informed consent~* Suffer from atypical, basilar or hemiplegic migraine that is new onset or unstable.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Relationship Between Sleep Quality and Daytime-Nighttime Variations of Blood Pressure and Plasma Glucose Type I

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients between 18 and 60 years of age~* Who have given their written consent to participate in this study~* Who are affiliated to the French social security system~* Are able to travel to Grenoble University Hospital~* Type I diabetes in reference to the 1997 criteria (American Diabetes Association) without any recent cetoacidosis or severe hypoglycaemia during the previous month and with a HbA1c \< 10% during the previous month.~* Normal blood pressure or essential hypertension light or moderate (SBP) at rest in the sitting position \>= 140 mmHg and \< 180 mmHg and/or PAD \>= 90 mmHg et \< 110 mmHg), with or without treatment.~Exclusion Criteria:~* Non stabilised diabetes with at least one episode of acidoketosis decompensation or hypoglycemic coma during the previous month.~* Diabetic nephropathy patent stage 4 with a creatinine \> 150 mol / L and / or creatinine clearance \<50 ml / min~* Diabetic nephropathy in evolution~* Severe hypertension (SBP at rest in the sitting position \>= 180 mmHg and/or DBP \>= 110 mmHg)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Phase 1b Study of CAR2Anti-CEA CAR-T Cell Hepatic Infusions for Pancreatic Carcinoma Patients With CEA+ Liver Metastases

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must have documented CEA+ pancreatic adenocarcinoma liver metastases and have failed greater than or equal to 1 line of conventional systemic therapy.~* Must have at least evaluable liver metastases.~* Must have a life-expectancy at least 12 weeks.~* Patients must be willing and able to comply with the study schedule and all other protocol requirements.~* Females of childbearing potential must have 2 negative pregnancy tests, agree to pregnancy tests during the study, and sexually active female and male patients must be willing to use an effective birth control method to avoid pregnancy.~Exclusion Criteria:~* Subjects who have received an investigational study drug within 14 days of leukapheresis or 28 days before receiving first dose of study drug.~* Subjects who have received any approved anticancer medication within 14 days of leukapheresis or 14 days before receiving the first dose of study drug.~* Have any unresolved toxicity greater than Grade 2 from previous anticancer therapy.~* Have a history of confirmed metastases outside the peritoneal cavity, lungs, or liver.~* More than 50% replacement of one or both liver lobes with tumor.~* Has tumor causing biliary obstruction not amenable to stenting.~* Have a high volume of lung or peritoneal metastases.~* Has received any CAR cell line therapies.~* Has any clinically significant low baseline lab results for hemoglobin, platelet counts, and neutrophil counts at screening.~* Has untreated or ongoing intra-abdominal infection or bowel obstruction.~* Has any clinically significant elevated baseline lab results for serum creatinine, AST, and total bilirubin (except for patients in whom hyperbilirubinemia is attributed to Gilbert's syndrome), and alkaline phosphatase at screening regardless of causality.~* Known HIV or acquired immunodeficiency syndrome-related illness, acute or history of chronic hepatitis B or C.~* Female patients who are pregnant or breastfeeding.~* Have active bacterial, viral, or fungal infections.~* Has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent study participation.~* Left ventricular ejection fraction (LVEF) \< 40%.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CAR2 Anti-CEA CAR-T cell (Type: EXPERIMENTAL): 3 doses of CAR2 Anti-CEA CAR-T cells for each cycle; up to 3 additional cycles received per investigator discretion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Tolerability and Efficacy of BVS857 in Severe Burn Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Burn injury comprising 2nd degree deep partial thickness and/or 3rd degree full thickness burns, ≥20% total body surface area with expected need for surgical intervention and not exceeding the sum of age plus burn size of 100 (Baux score)~* Dosing must occur within 8-12 days post-burn~* Subjects must weigh at least 45kgs (for group 1 with doses of 0.03mg/kg) and be under 100 kg to participate in the study~Exclusion Criteria:~* Spinal cord injury~* Hypoxic brain injury (Glasgow Coma Scale (GCS) \<8) at screening~* True conductive electric burn with suspected neurologic injury~* Uncontrolled diabetes with HbA1c \> 10% at screening, or known history of hypoglycemia,~* History of or active peripheral neuropathy or seizure disorder~* Systemic corticosteroids : \> 10mg/d of prednisone or equivalent, other investigational treatments (excluding investigational dressings), medications for weight loss including megestrol acetate, androgens or oral beta agonists

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- BVS857 Grp 1A open label (Type: EXPERIMENTAL): 0.03 mg/kg of BVS857intravenously in open label manner
- BVS857 Group 1B/1C, 2, 3, 4 Double Blind (Type: EXPERIMENTAL): None
- Placebo Group 1B/1C, 2, 3, 4 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Simvastatin For Intracerebral Hemorrhage Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with CT evidence of ICH admitted within 24 hours of onset of symptoms.~Exclusion Criteria:~* Age \< 18 or \> 85~* Admission Glasgow Coma Score (GCS) \< 6~* ICH volume \< 10 cc~* ICH secondary to trauma, aneurysm, Arterio-Venous Malformation (AVM), tumor or post surgical~* Multiple ICH~* Associated Subdural hematoma or significant Subarachnoid hemorrhage~* History of prior neurologic disease with modified Rankin Scale (mRS) \> 1~* Hematoma evacuation, hemicraniectomy, clot lysis~* Myopathy~* Active Liver disease~* Pregnancy~* Statin allergy~* Patients on statins prior to admission~* Patients with an acute indication for statin therapy (Unstable angina)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- I (Type: EXPERIMENTAL): Simvastatin Group
- II (Type: PLACEBO_COMPARATOR): Placebo Group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Posture on Left Ventricular (LV) Transvenous Lead Capture Thresholds (EXPECT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Greater than 18 years of age and able to provide informed consent~* Planned placement of a Medtronic LV pacing lead and a Medtronic ICD generator with LVCM technology~* Geographically stable and able to follow-up for a period of at least six months post-procedure at The Heart Hospital Baylor Plano~* Willingness to comply with the requirements of the protocol~Exclusion Criteria:~* Life expectancy of less than six months~* Plans for or significant possibility of pregnancy during the required follow-up window~* Significant cardiovascular surgery planned within six months following ICD implant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Medtronic passive fixation LV lead (Type: EXPERIMENTAL): Medtronic 4195 Active Fixation LV lead and Medtronic passive fixation LV lead arms will both have same follow-up testing and schedule
- Medtronic 4195 Active Fixation LV Lead (Type: EXPERIMENTAL): Medtronic 4195 Active Fixation LV lead and Medtronic passive fixation LV lead arms will both have same follow-up testing and schedule

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Dextromethorphan in Treating Patients With Fatigue Caused by Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of malignancy~  * Must be undergoing active treatment for malignancy which may include hormonal therapy (e.g., tamoxifen citrate or leuprolide acetate), but not radiotherapy alone~* Fatigue score ≥ 4 on a verbal analogue scale of 0 to 10~* No untreated cancer-related anemia~PATIENT CHARACTERISTICS:~* Hemoglobin \> 10 g/dL~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Able to swallow pills~* No known allergy to dextromethorphan hydrobromide~* No patients known to be phenotypically poor metabolizers of CYP2D6~* No untreated hypothyroidism~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* Prior single-dose inhibitors (e.g., ranitidine or cimetidine) for hypersensitivity prophylaxis allowed~* Erythropoietic growth factor therapy of \> 8 weeks duration allowed~* No concurrent CYP2D6 inducers or inhibitors~* No concurrent monoamine oxidase inhibitors~* No other concurrent medications containing dextromethorphan hydrobromide~* No concurrent over-the-counter medication, herbal product, vitamin, food supplement, or any other type of special product unless permission to continue use is obtained from the Principal Investigator~* No other concurrent anticancer investigational agents or therapies

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Concurrent Chemoradiation Therapy to Treat Locally Advanced Cervical Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Previously untreated, histologically confirmed cervical cancer~* One of following histologic types Squamous carcinoma, adenocarcinoma, adenosquamous carcinoma~* Age: 20-75 years~* GOG performance status: 0-2~* Adequate organ function Bone marrow: WBC ≥ 3,000/mm3, ANC ≥ 1,500/mm3, Platelet ≥ 100X103/mm3, Hb ≥ 10.0 g/dl Kidney: Creatinine \< 1.25 × UNL, Liver : AST, ALT \< 3 × UNL, T- bilirubin \< 1.5 mg/ mm3~* Contraception during study treatment~* Informed consent~Exclusion Criteria:~* Previous chemotherapy or pelvic radiation therapy~* Hormone therapy within 4 weeks~* Concomitant malignancy within 5 years except cured basal cell carcinoma of skin~* Uncontrolled medical disease~* Pregnant or lactating woman~* Etc.

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- CCRT weekly carboplatin (Type: EXPERIMENTAL): Concurrent chemoradiation therapy with weekly carboplatin
- CCRT weekly cisplatin (Type: ACTIVE_COMPARATOR): Concurrent chemoradiation therapy with weekly cisplatin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Feeding Infant Formula With Enriched Protein Fractions in the US

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Singleton, 0-90 days of age at randomization~* Term infant with birth weight of a minimum of 2500 grams~* Receiving at least 75% of the recommended caloric intake from cow's milk-based infant formula~* Parent or legally authorized representative attending study visits reads, understands, and speaks English~* Signed Informed Consent and Protected Health Information authorization~Exclusion Criteria:~* History of underlying metabolic or chronic disease, congenital malformation, or immunocompromised~* Feeding difficulties or formula intolerance~* Infant born small for gestational age~* Infant born from a mother who was diabetic at childbirth~* History of seizures or neurological disorders or infant with known head/brain disease/injury

- Gender: ALL
- Minimum Age: None
- Maximum Age: 90 Days
- Healthy Volunteers: t

Study Arms:
- Cow's milk-based infant formula (Type: ACTIVE_COMPARATOR): None
- Cow milk-based infant formula with enriched protein fractions (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Passive Prophylaxis of Lyme Disease Using Permethrin Treated Clothes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Summer camp staff at Tomahawk Scout Reservation~* Works in an outdoor environment~* Sleeps in an outdoor environment (platform tent)~* Present for the entire camp season (June - August)~* Informed consent~Exclusion Criteria:~* Contraindication, allergy or previous reaction to permethrin~* Inability of subject or surrogate (e.g., parent if \< 18 years of age) to provide informed consent

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Permethrin treatment of clothing (Type: EXPERIMENTAL): 0.5% permethrin sprayed one time on uniform shorts, pants, and socks
- Placebo (Type: SHAM_COMPARATOR): Water sprayed on uniform shorts, pants, and socks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy